Brokerages Set Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target at $12.00

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPHGet Rating) (TSE:AUP) have earned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $12.00.

Several equities analysts recently commented on the stock. StockNews.com began coverage on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. SVB Leerink reduced their price target on shares of Aurinia Pharmaceuticals from $17.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, November 4th. Oppenheimer lowered shares of Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, November 4th. Royal Bank of Canada reduced their price target on shares of Aurinia Pharmaceuticals from $18.00 to $10.00 and set an “outperform” rating for the company in a research report on Friday, November 4th. Finally, HC Wainwright reduced their price target on shares of Aurinia Pharmaceuticals from $26.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, November 7th.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tcwp LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth approximately $25,000. Total Clarity Wealth Management Inc. acquired a new stake in Aurinia Pharmaceuticals in the 2nd quarter valued at $26,000. Geneos Wealth Management Inc. grew its stake in Aurinia Pharmaceuticals by 54.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 1,142 shares during the period. Nisa Investment Advisors LLC acquired a new stake in Aurinia Pharmaceuticals in the 2nd quarter valued at $34,000. Finally, Lazard Asset Management LLC grew its stake in Aurinia Pharmaceuticals by 164.7% in the 1st quarter. Lazard Asset Management LLC now owns 5,300 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 3,298 shares during the period. Institutional investors and hedge funds own 35.20% of the company’s stock.

Aurinia Pharmaceuticals Stock Up 4.9 %

Shares of Aurinia Pharmaceuticals stock opened at $4.88 on Tuesday. The firm has a market capitalization of $693.50 million, a P/E ratio of -5.88 and a beta of 0.92. The company has a 50 day moving average price of $6.71 and a 200 day moving average price of $8.73. Aurinia Pharmaceuticals has a 52 week low of $4.49 and a 52 week high of $24.45.

About Aurinia Pharmaceuticals

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Read More

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.